TNFRSF8 and systemic mastocytosis: In addition, BMMC from SM patients also showed a greater rate of positivity for CD30 (63% vs. 5%, p = 0.001) and CD123 (38% vs. 3%, p = 0.001) than normal/reactive BMMC (Table 2, Figure 1C,E).